drugset
drugset / Trial / NCT04228302

Safety, Tolerability, and Pharmacokinetics of Oral EC5026 in Healthy Subjects

NCT04228302 ↗

Phase 1 Completed 40 enrolled EicOsis Human Health Inc. National Institute of Neurological Disorders and Stroke (NINDS) · collab
RandomizedParallel-groupDouble-blindOther

Summary

This is a first-in-human study with EC5026, a new drug candidate intended to treat neuropathic pain. The purpose of the study is to provide initial safety, tolerability, and pharmacokinetics data of single ascending oral doses of EC5026 in healthy subjects.

Timeline

Start
2019-12-09
Primary completion
2020-07-07
Completion
2020-07-07

Drugs

EvaluationDrugModalityDoseRoute
Subject EC5026 Unknown 0.5 mg Oral
Subject EC5026 Unknown 2 mg Oral
Subject EC5026 Unknown 8 mg Oral
Subject EC5026 Unknown 16 mg Oral
Subject EC5026 Unknown 24 mg Oral

Indications

No indication recorded.